Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
HONG KONG, Jun 27, 2023 - (ACN Newswire) - Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, the "Group", HKEX stock code: 0460) is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharm"), a non-wholly owned subsidiary of Company, has received a drug registration approval from the National Medical Products Administration (the "NMPA") of China of Anaprozole Sodium Enteric-coated Tablet for the treatment of duodenal ulcer. It is the first drug approved for marketing by Xuanzhu Biopharm, which marks a new milestone for Xuanzhu Biopharm from R&D to commercialization.
Anaprozole Sodium Enteric-coated Tablet is currently the first and only proton pump inhibitor (PPI) fully independently developed in China. Its Phase I-III clinical studies are all based on the Chinese population, so it is more suitable for Chinese patients. Anaprozole tablets can effectively inhibit the secretion of gastric acid and has the characteristics of fast onset, stable therapeutic effect, less individual variation, and long half-life. Clinical data shows that Anaprozole is metabolized through multiple CYP enzymes and non-enzymes, so the risk of drug to drug interactions is low when it is used in combination with other drugs. The drug and its metabolites are excreted through the gut and kidney, which provides safer medication options for patients with renal insufficiency.
In addition, Anaprozole Sodium Enteric-coated Tablet is not only used to treat duodenal ulcer, but also is expanding its new indication for the treatment of adult reflux esophagitis (RE). Its Phase II clinical trial has completed the enrollment of subjects, and its Phase III clinical trial is planned to initiate by the end of 2023.
Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical Holdings Group commented, "We are an innovative pharmaceutical company with roots in China and a global perspective. Our group is committed to the continuous research and development, production and commercialization of class 1 drugs with core proprietary intellectual property rights to address unmet clinical medical needs. PPI is the preferred drug choice for the treatment of peptic ulcer. The approval of Xuanzhu Biopharm's Anerazole Sodium Enteric-Coated Tablets will bring more treatment options for patients. It is also a shot in the arm for injecting billions of dollars into the acid suppressant market. According to statistics, the number of patients with peptic ulcer in China reached over 70 million in 2021, and the total market sales size of proton pump inhibitors in China is nearly RMB30 billion, of which the oral proton pump inhibitor market is nearly RMB13 billion, which reflects that the market is relatively large. Meanwhile, based on their excellent clinical performance, Anaprozole Sodium Enteric-coated Tablet will be gladly accepted by doctors and patients and will have huge commercial potential and clinical value in the future."
About Sihuan Pharmaceutical Holdings Group Ltd. Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical Holdings Group Ltd. is an international medical aesthetic and biopharmaceutical company led and driven by innovation, with a leading independent production, and R&D technology platform, a rich global product pipeline and a mature and excellent sales system. Focusing on high-growth therapeutic areas such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine and industrial hemp, it adheres to its overall strategic objective of "Adhering to the full-speed promotion of a two-wheeled strategy of Sihuan medical aesthetics and biopharmaceuticals" to build a leading medical aesthetics and biopharmaceutical company in China.
About Xuanzhu Biopharmaceutical Co., Ltd. Xuanzhu Biopharmaceutical is the innovative drug subsidiary of Sihuan Pharmaceutical. It is an innovative pharmaceutical company with roots in China and a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the continuous research and development, production and commercialization of class 1 drugs with core proprietary intellectual property rights to address unmet clinical medical needs. The company has a team with extensive experience in the development and industrialisation of innovative drugs. Having been involved in the research of digestion, oncology and non-alcoholic steatohepatitis for many years, the company has a deep understanding and international vision of the development of new drugs in related fields and their future development direction. The company has two R&D platforms: small molecule chemistry and large molecule biologics. The dual engines drive the company's innovation and development, forming a product pipeline that covers small molecule, monoclonal antibodies, bispecific antibodies, antibody-drug conjugate (ADC) and other types of products. The company adheres to the strategic concept of "innovation driven, promoting the development of new drugs in China and serving human health", and the values of "open innovation, courageous commitment, overcoming difficulties and scientific rigor". With a focus on unmet clinical needs, the company continues to develop new class 1 drugs with international competitiveness, and is committed to developing into a first-class innovative pharmaceutical company with independent research and development, production, and sales capabilities.
For more information about Sihuan Pharmaceutical, please visit the Company's website at https://www.sihuanpharm.com/
Issued by Porda Havas International Finance Communications Group for and on behalf of Sihuan Pharmaceutical Holdings Group Ltd. For further information, please contact us at sihuanpharm.hk@pordahavas.com.
Source: Sihuan Pharmaceutical Holdings Group Ltd. Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Related Press Release
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical: The NDA of the New Drug, independently developed for the treatment of advanced breast cancer was accepted by NMPA | October 17 2023 16:01 JST | | Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023 | October 13 2023 18:07 JST | | Sihuan Pharmaceutical (0460.HK) Announces 2023 Interim Results, Revenue amounted to RMB1,055.7 million | August 31 2023 13:50 JST | | Sihuan Pharmaceutical (0460.HK): Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval For Clinical Trial | July 05 2023 09:49 JST | | Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, progresses at full speed in innovative research and development, Presents major research results of birociclib, the start product, at the international stage in ASCO | June 08 2023 21:18 JST | | Sihuan Pharmaceutical (0460.HK) Announces 2022 Annual Results | March 24 2023 19:16 JST | | Sihuan Pharmaceutical (0460.HK): Huisheng Biopharmaceutical Successfully Completes A+ Round of Financing, Accelerating the Layout of Diabetes and Complications | January 04 2023 09:55 JST | | Sihuan Pharmaceutical (0460.HK): Respond to the special directives to combat illegal medical aesthetics services, Advocate 'Positive Energy' in China's Medical Aesthetics Industry | August 11 2021 16:55 JST | | Sihuan Pharmaceutical Launched an Equity Incentive Plan to Inject New Impetus for the Company's Growth | August 27 2020 16:05 JST | | Sihuan Pharmaceutical Announces 2020 Interim Results | August 25 2020 21:26 JST | | More Press release >> |
Latest Press Release
 Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan May 23, 2025 17:29 JST
|  Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements May 23, 2025 13:36 JST
|  NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework May 23, 2025 13:35 JST
|  Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India May 23, 2025 12:17 JST
|  Honda Reaches 500 Million-Unit Milestone in Cumulative Global Motorcycle Production May 23, 2025 11:32 JST
|  Five Toyota Group Companies to Accelerate Skill Development and Innovation in AI and Software May 23, 2025 10:51 JST
|  MHI Conducts Flight Test for Hybrid-Type Medium-Sized UAV May 22, 2025 13:35 JST
|  Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 May 21, 2025 15:00 JST
|  New RAV4 Makes World Premiere in Japan May 21, 2025 14:09 JST
|  Naoris Protocol Begins Token Sale for First Post-Quantum Infrastructure Layer May 21, 2025 14:00 JST
|  MHI Marine Machinery Begin Demonstration Testing of Methane Oxidation Catalyst System for Marine LNG Engines May 20, 2025 13:51 JST
|  MHI Launches 'Prismo,' a New Brand Eco-Friendly Next-Generation AGT May 19, 2025 16:14 JST
|  Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro May 16, 2025 17:21 JST
|  Premiere of New bZ Woodland BEV Focused on Driving Performance and Spaciousness in North America May 16, 2025 16:35 JST
|  Mitsubishi Heavy Industries Activates New Driving Force for Data Center Business in the United States May 16, 2025 15:43 JST
|  MHI Thermal Systems Receives JSRAE Technology Award May 15, 2025 20:08 JST
|  Honda and Quemix Co-develop a New, World's First Quantum State Readout Technology May 15, 2025 13:37 JST
|  Mitsubishi Electric Building Solutions Launches a New Projection-type Hall Lantern for Overseas Markets May 15, 2025 11:00 JST
|  MHI Starts Operation of New CO2 Capture Pilot Plant at KEPCO's Himeji No.2 Power Station May 14, 2025 16:50 JST
|  Making Anime More Interesting and Taking it into the Future, Launch of Three New Projects May 14, 2025 11:00 JST
|
More Latest Release >>
|